Related Experiment Video
Updated: Aug 3, 2026
Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin
Published on: April 30, 2019
Alemtuzumab-associated diffuse alveolar damage - a case report
Antonios Bayas1, Martina Menacher2, Martin Schwaiblmair3
1Neurology and Clinical Neurophysiology, University Hospital of Augsburg, Stenglinstrasse 2, 86156, Augsburg, Germany. antonios.bayas@uk-augsburg.de.
Background:
Identifying causes of alemtuzumab induced respiratory symptoms in Multiple Sclerosis (MS) patients is crucial.
Case Presentation:
We report a case of diffuse alveolar damage (DAD) in a patient with MS after the first course of alemtuzumab treatment. A 42-year-old female developed progressive non-productive cough and exertional dyspnea 2 months after alemtuzumab treatment. DAD was diagnosed histopathologically by lung biopsy. The patient recovered completely, alemtuzumab was not continued.
Conclusions:
Our case highlights another pathomechanism for non-infective lung-disorders in alemtuzumab treated MS patients. DAD is a potential, albeit rare side effect of alemtuzumab, broadening the spectrum of non-infective lung disorders that should be considered in the diagnostic work-up.
More Related Videos
09:27Multicellular Human Alveolar Model Composed of Epithelial Cells and Primary Immune Cells for Hazard Assessment
Published on: May 6, 2020
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
01:10Atelectasis II: Pathophysiology
01:23Chronic Obstructive Pulmonary Disease II: Emphysema